Jacobs Levy Equity Management’s Viridian Therapeutics VRDN Stock Holding History

Jacobs Levy Equity Management’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.86M	Buy	+101,414	New	+$1.63M	0.01%	610

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Jacobs Levy Equity Management's VRDN Position: Q2 2026 in Review

Jacobs Levy Equity Management opened a new position in Viridian Therapeutics (VRDN) in Q2 2026: 101,414 shares worth $1.86M. The stake represents 0.01% of the portfolio and ranks #610 among its holdings.

212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Jacobs Levy Equity Management held 101,414 shares of Viridian Therapeutics worth $1.86M as of Q2 2026.
Viridian Therapeutics was a new Jacobs Levy Equity Management position in Q2 2026.
Viridian Therapeutics made up 0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #610 holding.
212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.